Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors
Stock Information for Bio-Path Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.